Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EUROCONDOR

Financiado

Cerrado

European Consortium for the Early Treatment of Diabetic Retinopathy

Diabetic retinopathy (DR), the leading cause of blindness among working-age individuals in developed countries has been classically considered to be a microcirculatory disease of the retina. However, there is growing evidence to s... ver más

30/06/2016

FUNDACIO HOSPITAL...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

FUNDACIO HOSPITAL UNIVERSITARI VALL HEBRON -... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 33M€

Fecha límite participación Sin fecha límite de participación.

Ver 18 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-06-30 No tenemos la información de la convocatoria

0% 77% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

18 Participantes

FUNDACIO HOSPITAL UNIVERSITA...

0.00€ | Lider

UNISR

N.D. | Participante

BCN PEPTIDES

N.D. | Participante

ASTON U

N.D. | Participante

Proyectos interesantes

EGRET-Plus

Medical Technol...

Data Science

4M€ Cerrado

RED2018-102499-T

Medical Technol...

Data Science

20K€ Cerrado

PID2020-114585RA-I00

Medical Technol...

Data Science

67K€ Cerrado

SAF2014-62114-EXP

Medical Technol...

Ophthalmology

73K€ Cerrado

DESARROLLO CLÍNICO DE RETSIT@, UN FÁRMACO NEU...

Medical Technol...

Pharmaceutical...

250K€ Cerrado

RetinDR

Medical Technol...

Pharmaceuticals

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

FUNDACIO HOSPITAL UNIVERSITARI VALL HEBRON -... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 33M€

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Diabetic retinopathy (DR), the leading cause of blindness among working-age individuals in developed countries has been classically considered to be a microcirculatory disease of the retina. However, there is growing evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR. For this reason, it is reasonable to hypothesize that therapeutic strategies based on neuroprotection will be effective not only in preventing or arresting retinal neurodegeneration but also in preventing the development and progression of the early stages of DR (ie. microaneurysms and/or retinal thickness). EUROCONDOR (European Consortium for the Early Treatment of Diabetic Retinopathy) is a solid and well balanced consortium (ophthalmologists, endocrinologists, basic researchers) which has been created in order to implement the first clinical trial using eye drops for treatment of the early stages of DR. The participants are top leaders in their field and central readings will be performed by the Coordinating Centre of the European Vision Institute Clinical Research Network (EVICR.Net). The main objectives of the project are the following: Primary objective: To assess whether the selected neuroprotective drugs (brimonidine and somatostatin) administered topically are able to prevent or arrest neurodegeneration, as well as the development and progression of the early stages of DR. Secondary objectives: 1) To determine the prevalence of functional abnormalities related to neurodegeneration in those patients without or with minimal microvascular damage under ophthalmoscopic examination. 2) To compare the effectiveness of the selected drugs. 3) To evaluate the local and systemic adverse effects of the selected drugs. 4) To identify those patients most prone to progressive worsening (characterization of phenotypes and circulating biomarkers). 5) To determine the molecular mechanisms by which the selected drugs exert their beneficial effects.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores